image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.83
-0.352 %
$ 144 M
Market Cap
-2.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SGHT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.83 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SGHT stock under the base case scenario is HIDDEN Compared to the current market price of 2.83 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SGHT stock under the best case scenario is HIDDEN Compared to the current market price of 2.83 USD, Sight Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
81.1 M REVENUE
13.63%
-57.3 M OPERATING INCOME
31.78%
-55.5 M NET INCOME
35.59%
-47.2 M OPERATING CASH FLOW
37.89%
-791 K INVESTING CASH FLOW
18.45%
1.1 M FINANCING CASH FLOW
-11.54%
20.2 M REVENUE
-5.68%
-11.2 M OPERATING INCOME
11.24%
-11.1 M NET INCOME
10.24%
600 K OPERATING CASH FLOW
106.18%
-51 K INVESTING CASH FLOW
36.25%
-162 K FINANCING CASH FLOW
-23.86%
Balance Sheet Sight Sciences, Inc.
image
Current Assets 163 M
Cash & Short-Term Investments 138 M
Receivables 14.3 M
Other Current Assets 10.5 M
Non-Current Assets 3.78 M
Long-Term Investments 0
PP&E 3.1 M
Other Non-Current Assets 682 K
Current Liabilities 12.3 M
Accounts Payable 1.73 M
Short-Term Debt 2.79 M
Other Current Liabilities 7.73 M
Non-Current Liabilities 34.2 M
Long-Term Debt 32.6 M
Other Non-Current Liabilities 1.56 M
EFFICIENCY
Earnings Waterfall Sight Sciences, Inc.
image
Revenue 81.1 M
Cost Of Revenue 11.9 M
Gross Profit 69.2 M
Operating Expenses 126 M
Operating Income -57.3 M
Other Expenses -1.73 M
Net Income -55.5 M
RATIOS
85.34% GROSS MARGIN
85.34%
-70.66% OPERATING MARGIN
-70.66%
-68.53% NET MARGIN
-68.53%
-46.21% ROE
-46.21%
-33.33% ROA
-33.33%
-37.23% ROIC
-37.23%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sight Sciences, Inc.
image
Net Income -55.5 M
Depreciation & Amortization 614 K
Capital Expenditures -791 K
Stock-Based Compensation 14.6 M
Change in Working Capital -9.13 M
Others -4.45 M
Free Cash Flow -48 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sight Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for SGHT of $7.75 , with forecasts ranging from a low of $5 to a high of $10 .
SGHT Lowest Price Target Wall Street Target
5 USD 76.68%
SGHT Average Price Target Wall Street Target
7.75 USD 173.85%
SGHT Highest Price Target Wall Street Target
10 USD 253.36%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Sight Sciences, Inc.
image
Sold
0-3 MONTHS
2.29 M USD 6
3-6 MONTHS
574 K USD 6
6-9 MONTHS
290 K USD 5
9-12 MONTHS
325 K USD 5
Bought
2.12 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Jan 03, 2025
Sell 11 K USD
Badawi David
Chief Technology Officer
- 3111
3.522 USD
2 weeks ago
Jan 03, 2025
Sell 17.1 K USD
HAYDEN JEREMY B.
Chief Legal Officer
- 4864
3.522 USD
2 weeks ago
Jan 03, 2025
Sell 35.6 K USD
Bauerlein Alison
Chief Financial Officer
- 10102
3.522 USD
2 weeks ago
Jan 02, 2025
Sell 44 K USD
Badawi Paul
President and CEO
- 12236
3.597 USD
1 month ago
Dec 06, 2024
Bought 19.2 K USD
Raheja Manohar K.
EVP, Research & Development
+ 5000
3.85 USD
1 month ago
Dec 03, 2024
Bought 13.1 K USD
Raheja Manohar K.
EVP, Research & Development
+ 3376
3.89 USD
1 month ago
Nov 29, 2024
Bought 18.4 K USD
Raheja Manohar K.
EVP, Research & Development
+ 4624
3.988 USD
2 months ago
Nov 19, 2024
Bought 7.4 K USD
Raheja Manohar K.
EVP, Research & Development
+ 2000
3.7 USD
1 month ago
Nov 21, 2024
Bought 2.06 M USD
Encrantz Staffan
director, 10 percent owner:
+ 551802
3.73 USD
1 month ago
Nov 21, 2024
Sell 2.06 M USD
Encrantz Staffan
director, 10 percent owner:
- 551802
3.73 USD
3 months ago
Oct 18, 2024
Sell 122 K USD
Link Matthew
Chief Commercial Officer
- 20487
5.977 USD
2 months ago
Oct 21, 2024
Sell 122 K USD
Link Matthew
Chief Commercial Officer
- 21831
5.609 USD
3 months ago
Oct 16, 2024
Sell 122 K USD
Link Matthew
Chief Commercial Officer
- 20734
5.905 USD
3 months ago
Oct 17, 2024
Sell 122 K USD
Link Matthew
Chief Commercial Officer
- 20970
5.839 USD
3 months ago
Oct 02, 2024
Sell 76.2 K USD
Badawi Paul
President and CEO
- 12727
5.986 USD
3 months ago
Oct 01, 2024
Sell 29.7 K USD
HAYDEN JEREMY B.
Chief Legal Officer
- 4878
6.08 USD
3 months ago
Oct 02, 2024
Sell 19 K USD
Badawi David
Chief Technology Officer
- 3167
5.986 USD
3 months ago
Oct 01, 2024
Sell 61.6 K USD
Bauerlein Alison
Chief Financial Officer
- 10130
6.08 USD
3 months ago
Oct 01, 2024
Sell 20.7 K USD
Park Sam Boong
Chief Operating Officer
- 3403
6.08 USD
6 months ago
Jul 02, 2024
Sell 31.4 K USD
HAYDEN JEREMY B.
Chief Legal Officer
- 5055
6.212 USD
6 months ago
Jul 01, 2024
Sell 20.1 K USD
Badawi David
Chief Technology Officer
- 3128
6.417 USD
6 months ago
Jul 01, 2024
Sell 80.7 K USD
Badawi Paul
President and CEO
- 12569
6.417 USD
6 months ago
Jul 02, 2024
Sell 21.9 K USD
Park Sam Boong
Chief Operating Officer
- 3525
6.212 USD
6 months ago
Jul 02, 2024
Sell 65.2 K USD
Bauerlein Alison
Chief Financial Officer
- 10497
6.212 USD
8 months ago
May 17, 2024
Sell 70.9 K USD
Bauerlein Alison
Chief Financial Officer
- 13066
5.424 USD
9 months ago
Apr 03, 2024
Sell 24.9 K USD
HAYDEN JEREMY B.
Chief Legal Officer
- 4893
5.079 USD
9 months ago
Apr 03, 2024
Sell 63.8 K USD
Badawi Paul
President and CEO
- 12571
5.079 USD
9 months ago
Apr 03, 2024
Sell 15.9 K USD
Badawi David
Chief Technology Officer
- 3128
5.079 USD
9 months ago
Apr 03, 2024
Sell 17.3 K USD
Park Sam Boong
Chief Operating Officer
- 3414
5.079 USD
9 months ago
Apr 03, 2024
Sell 51.4 K USD
Bauerlein Alison
Chief Financial Officer
- 10123
5.079 USD
1 year ago
Jan 17, 2024
Sell 82.2 K USD
Badawi Paul
President and CEO
- 15917
5.164 USD
1 year ago
Jan 17, 2024
Sell 17.6 K USD
Badawi David
Chief Technology Officer
- 3414
5.164 USD
1 year ago
Jan 17, 2024
Sell 23.4 K USD
HAYDEN JEREMY B.
Chief Legal Officer
- 4538
5.164 USD
1 year ago
Jan 17, 2024
Sell 28.1 K USD
Park Sam Boong
Chief Operating Officer
- 5443
5.164 USD
1 year ago
Dec 27, 2023
Sell 16.7 M USD
D1 Capital Partners L.P.
10 percent owner
- 2852036
5.86 USD
1 year ago
Nov 30, 2023
Bought 487 K USD
Encrantz Staffan
director, 10 percent owner:
+ 140777
3.4568 USD
1 year ago
Nov 29, 2023
Bought 11.3 K USD
Encrantz Staffan
director, 10 percent owner:
+ 3223
3.5 USD
1 year ago
Nov 28, 2023
Bought 877 K USD
Encrantz Staffan
director, 10 percent owner:
+ 253669
3.4578 USD
1 year ago
Nov 27, 2023
Bought 816 K USD
Encrantz Staffan
director, 10 percent owner:
+ 246331
3.3124 USD
1 year ago
Nov 24, 2023
Bought 67.4 K USD
Encrantz Staffan
director, 10 percent owner:
+ 21855
3.0852 USD
1 year ago
Nov 22, 2023
Bought 103 K USD
Encrantz Staffan
director, 10 percent owner:
+ 41085
2.4999 USD
1 year ago
Nov 21, 2023
Bought 170 K USD
Encrantz Staffan
director, 10 percent owner:
+ 68477
2.4758 USD
1 year ago
Nov 20, 2023
Bought 178 K USD
Encrantz Staffan
director, 10 percent owner:
+ 79234
2.2489 USD
1 year ago
Nov 17, 2023
Bought 277 K USD
Encrantz Staffan
director, 10 percent owner:
+ 126664
2.1892 USD
1 year ago
Nov 16, 2023
Bought 678 USD
Encrantz Staffan
director, 10 percent owner:
+ 339
2 USD
1 year ago
Nov 14, 2023
Bought 6.91 K USD
Encrantz Staffan
director, 10 percent owner:
+ 3462
1.997 USD
2 years ago
May 13, 2022
Bought 2.46 M USD
Encrantz Staffan
director:
+ 300000
8.2 USD
2 years ago
May 13, 2022
Bought 41.4 K USD
Selnick Jesse
Chief Financial Officer
+ 5000
8.28 USD
3 years ago
Dec 01, 2021
Bought 1.44 M USD
Encrantz Staffan
Director
+ 62959
22.92 USD
3 years ago
Dec 01, 2021
Bought 2.77 M USD
Encrantz Staffan
Director
+ 123931
22.36 USD
3 years ago
Dec 01, 2021
Bought 594 K USD
Encrantz Staffan
Director
+ 27716
21.43 USD
3 years ago
Nov 30, 2021
Bought 1.19 M USD
Encrantz Staffan
Director
+ 56836
20.96 USD
3 years ago
Nov 30, 2021
Bought 1.94 M USD
Encrantz Staffan
Director
+ 94969
20.4 USD
3 years ago
Nov 30, 2021
Bought 1.4 M USD
Encrantz Staffan
Director
+ 72135
19.44 USD
3 years ago
Nov 29, 2021
Bought 41.9 K USD
Encrantz Staffan
Director
+ 2200
19.06 USD
3 years ago
Nov 29, 2021
Bought 1.59 M USD
Encrantz Staffan
Director
+ 84254
18.84 USD
3 years ago
Nov 23, 2021
Bought 184 K USD
Selnick Jesse
Chief Financial Officer
+ 10000
18.4393 USD
3 years ago
Oct 18, 2021
Bought 12.6 M USD
Encrantz Staffan
Director
+ 527048
24 USD
3 years ago
Jul 19, 2021
Bought 16.8 M USD
D1 Capital Partners L.P.
10 percent owner
+ 700000
24 USD
7. News
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options Budget impact analysis published in the Expert Review of Ophthalmology journal Budget impact analysis published in the Expert Review of Ophthalmology journal globenewswire.com - 1 month ago
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. globenewswire.com - 1 month ago
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake Street Capital Markets Tom Stephan - Stifel Operator Thank you for standing by. My name is Janine, I will be your conference operator for today. seekingalpha.com - 2 months ago
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago. zacks.com - 2 months ago
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 3 months ago
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease globenewswire.com - 3 months ago
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY. globenewswire.com - 4 months ago
Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants Thomas Stephan - Stifel Joseph Conway - Needham & Company Felipe Lamar - Citi Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2024 Earnings Results Conference Call. seekingalpha.com - 5 months ago
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. zacks.com - 5 months ago
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 6 months ago
Sight Sciences Announces the Release of its First Sustainability Report The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives globenewswire.com - 7 months ago
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. globenewswire.com - 7 months ago
8. Profile Summary

Sight Sciences, Inc. SGHT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 144 M
Dividend Yield 0.00%
Description Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact 4040 Campbell Avenue, Menlo Park, CA, 94025 https://www.sightsciences.com
IPO Date July 15, 2021
Employees 214
Officers Mr. Jeremy B. Hayden J.D. Chief Legal Officer Dr. Manohar Raheja Ph.D. Executive Vice President of Research & Development Mr. Paul Badawi Co-Founder, President, Chief Executive Officer & Director Mr. Brenton Taylor Executive Vice President of Operations Ms. Alison Perry Bauerlein Chief Financial Officer & Treasurer Mr. Stephen B. Thau J.D. Secretary Dr. Reay H. Brown M.D. Chief Medical Officer Mr. Steve R. Tamayo Jr. Vice President and Chief Ethics & Compliance Officer Dr. David Badawi M.D. Founder, Chief Technology Officer & Director Mr. Matthew W. Link Chief Commercial Officer